Caredx announces third quarter 2025 financial results

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna) — the transplant company — a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the third quarter ended september 30, 2025. third quarter 2025 financial highlights revenue of $100.1 million, an increase of 21% year-over-year testing services revenue of.
CDNA Ratings Summary
CDNA Quant Ranking